AANP Family Nurse Practitioner (FNP) Certification ExamEvaluationHard
A 68-year-old male with a history of Type 2 Diabetes Mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) is currently on metformin 1000 mg twice daily. His current A1c is 7.8%. He reports no issues with metformin. Which of the following is the most appropriate next step in managing his T2DM?
- AAdd glipizide to his current regimen.
- BInitiate basal insulin at bedtime.
- CIncrease metformin to 1250 mg twice daily.
- DAdd empagliflozin to his current regimen.
Show answer & explanationAnswer & explanation
Correct answer: D. Add empagliflozin to his current regimen.
For patients with T2DM and established ASCVD, current guidelines recommend adding a GLP-1 receptor agonist or an SGLT2 inhibitor with proven cardiovascular benefit, regardless of A1c, as a second-line agent after metformin. Empagliflozin is an SGLT2 inhibitor with demonstrated cardiovascular benefits.
Why the other options are wrong
- A. Glipizide (a sulfonylurea) can lower A1c but does not offer cardiovascular protection and carries a risk of hypoglycemia, making it a less optimal choice compared to SGLT2 inhibitors or GLP-1 RAs in this patient.
- B. Basal insulin may be considered for A1c targets not met by oral agents, but an SGLT2 inhibitor or GLP-1 RA is preferred first-line for ASCVD patients due to specific cardiovascular outcome data.
- C. Increasing metformin dose is not the priority when a patient has ASCVD and specific agents with cardiovascular benefits are indicated.
T2DM with ASCVD Management
For patients with Type 2 Diabetes and established atherosclerotic cardiovascular disease, treatment intensification after metformin should prioritize agents with proven cardiovascular benefits, such as GLP-1 receptor agonists or SGLT2 inhibitors.
- Cardiovascular benefit is a primary consideration in this patient population.
- GLP-1 RAs and SGLT2 inhibitors are preferred second-line agents.
- This recommendation stands regardless of A1c target attainment solely by other means.
Memory trick: When T2DM meets ASCVD, pick the pill that protects the heart, not just glucose!